Fri, October 29, 2021

David Lebovitz Maintained (BPMC) at Hold with Increased Target to $111 on, Oct 29th, 2021

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-111-on-oct-29th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication
David Lebovitz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Increased Target from $96 to $111 on, Oct 29th, 2021.

David has made no other calls on BPMC in the last 4 months.



There is 1 other peer that has a rating on BPMC. Out of the 1 peers that are also analyzing BPMC, 0 agree with David's Rating of Hold.



This is the rating of the analyst that currently disagrees with David


  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Thursday, October 28th, 2021